Shanghai and Beijing - Viva Biotech (Shanghai) Co., Ltd. ("Viva Biotech") and Bejing Biocytogen Co., Ltd. (“Biocytogen”) and announced today a strategic collaboration to jointly accelerate the early-stage drug discovery.
The strategic collaboration will combine Biocytogen’s fully human antibody mouse platforms (including RenMab™, RenLite®, and RenNano®) of independent proprietary intellectual property with Viva Biotech’s world-leading structure-based, integrated drug discovery platform, to achieve synergies with Viva Biotech’s EFS (Equity-for-service) business model. The collaboration will allow the two companies to jointly promote innovative biologic drug discovery and development.
Viva Biotech operates a world-leading structure-based, integrated drug discovery platform, providing structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide for their preclinical stage innovative drug development, covering the full spectrum of our customers’needs for early stage drug discovery. As of June 30th, 2020, Viva Biotech has served 495 pharmaceutical customers worldwide, including top 10 global pharmaceutical companies and 29 “Fierce Biotech 15” promising biotech companies. Our EFS business also provides drug discovery and incubation services to high potential biotech start-ups around the world. Till now, the company has incubated and invested 56 early-stage companies, covering a variety of indications and cutting-edge medical areas, with a wide range of mechanisms.
Biocytogen has established a highly integrated antibody drug discovery platform based on genetically-modified animal models. With strong technological innovation capabilities, the company has built its collaboration with more than 2,000 partners, including 14 top pharmaceutical companies worldwide. Biocytogen has so far 3 innovative biologic drugs of collaboration entered phase I clinical trials, and several antibody drugs are about to enter the clinical trial application. With the steady progress of the “Project Integrum”, it is believed that more fully human antibody drugs of the pipeline will enter clinical studies in the future.
“We are very glad to witness the collaboration between Biocytogen and Viva Biotech,” said Dr. Yuelei Shen, CEO of Biocytogen. “Along with Viva Biotech, we will provide diversified and all-round support for highly innovative biotech start-ups, accelerate the research and development of innovative drugs, and provide help for more patients.”
Dr. Delin Ren, President of Viva Biotech said, “Biocytogen's fully human antibody mouse platform has an antibody coding format that is more similar to humans, which is easy for immunization, and is compatible with various antibody screening methods. The antibodies obtained are rich in diversity and better in druggability, which will effectively fill the gaps of Viva Biotech in the use of fully human antibody mice. The collaboration will further enhance the scalability of Viva Biotech’s EFS business model, thereby strengthening its ability in attracting and incubating more innovative startups.”